Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.
Researchers in the Appel lab have developed hydrogels for tumor inoculation that improve precision and statistical power in preclinical mouse models of cancer.